MedTrace Logo

EYE-TRAC Advance: Technology Verification (ETA-TV) Cohort 2

NCT02877732 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-05-30

Study results available
· View outcomes & findings →

Summary

This is a prospective multi-center cohort feasibility and exploratory study.

Conditions

  • Eye-tracking

Interventions

DEVICE

EYE-SYNC eye-tracking

The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.

OTHER

SCAT-3 subtests

Following subtests of SCAT-3 will be administered to the participant: Symptom, Balance, Orientation and Immediate memory

OTHER

DEM

Participant will be asked to read list of numbers out loud from a card

OTHER

Simple Reaction Time subtest of ANAM-SRT

Participants will perform Simple Reaction Time sub-test of ANAM-SRT test. They will be asked to click the mouse button every time they see an asterisk on the screen. Participants will perform ANAM-SRT 1 and ANAM-SRT 2 in this study.

OTHER

Level of Alertnesss

Participants will answer questions. This assessment is to assess their alertness level.

Sponsors & Collaborators

  • Brain Trauma Foundation

    collaborator OTHER

  • United States Department of Defense

    collaborator FED

  • Food and Drug Administration (FDA)

    collaborator FED

  • U.S. Army Medical Research and Development Command

    collaborator FED

  • Department of Health and Human Services

    collaborator FED

  • Stanford University

    lead OTHER

Principal Investigators

  • Jessica A Little, PhD · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2017-04-30
Completion
2017-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02877732 on ClinicalTrials.gov